临床试验登记· German CLL Study Group · ClinicalTrials.gov·· 14 小时前评分35
CLL-Frail2 2期试验评估体能适配策略下 zanubrutinib 单药或限时联合 sonrotoclax 治疗≥80岁及/或体弱初治 CLL 的疗效与安全性
A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL
导读
German CLL Study Group 新登记 CLL-Frail2 2期试验（NCT07899398），评估体能适配策略下 zanubrutinib 单药或限时联合 sonrotoclax 治疗初治 CLL 的疗效与安全性。拟纳入≥80岁及/或体弱患者，计划入组80人，尚未招募，拟于2026-12-01启动。
来源：临床试验登记 · clinicaltrials.gov